


Consolidated Financial Highlights

In the FY ended March 2016, business results fell significantly below the initial forecast due to yearlong weak demand in the core businesses. Fourth quarter results in particular were affected by a sudden demand slowdown in our customers' markets and the impact of the weak yen.



Previous year
¥404.1 billion

Although SSBR sales rose sharply, and the net sales of life sciences business showed growth, overall revenues declined due to a slump in elastomer product prices, weakness in the semiconductor market, and an abrupt second-half slowdown in the FPD market.

Previous year
¥364.7 billion

Net assets were lower, primarily because of a ¥10.3 billion year-on-year decrease in accumulated other comprehensive income. The equity ratio was 68.4%.

Previous year
¥38.1 billion

Income in the Petrochemical Products Business segment declined as higher profitability and income in the plastics business could not offset lower income in the elastomers business. Income in the Fine Chemicals and Other Products Business segment also declined on lower sales of semiconductor materials and display materials.

Previous year
10%


ROIC decreased as a result of factors including a year-on-year decrease in income, despite continuing investment to capture growth opportunities.



(FY) 2012 2013 2014 2015 2016

Previous year
8.7%

ROE decreased by 1.9 points because of factors including an increase in equity and a decrease of ¥5.9 billion in profit attributable to owners of parent.



(FY) 2012 2013 2014 2015 2016

Note: FY means year ended March 31